A Randomized, Double Blind, Double Dummy Multicenter Phase IIa Study to Assess Safety, Tolerability and Efficacy of GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection.
Latest Information Update: 26 Aug 2023
At a glance
- Drugs Lanopepden (Primary) ; Linezolid
- Indications Bacterial infections; Skin infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 11 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Feb 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
- 17 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.